| Literature DB >> 15110144 |
Abstract
Early recognition of potential QT/TdP liability is now an essential component of the drug discovery/drug development program. The hERG assay is an indispensable step and a high-quality assay must accompany any investigational new drug (IND) application. While it is the gold standard at present, the hERG assay is too labor-intensive and too low throughput to be used as a screen early in the discovery/development process. A variety of indirect high throughput screens have been used.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15110144 DOI： 10.1016/j.ceca.2004.01.008
Source DB: PubMed Journal: Cell Calcium ISSN： 0143-4160 Impact factor: 6.817